Benouaich-Amiel A - Search Results

1

MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities.

Crinière E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, Everhard S, Mokhtari K, Polivka M, Delattre JY, Hoang-Xuan K, Thillet J, Sanson M. Crinière E, et al. J Neurooncol. 2007 Jun;83(2):173-9. doi: 10.1007/s11060-006-9320-0. Epub 2007 Jan 12. J Neurooncol. 2007. PMID: 17219056

2

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, Thillet J, Delattre JY, Hoang-Xuan K, Sanson M. Houillier C, et al. Cancer. 2006 May 15;106(10):2218-23. doi: 10.1002/cncr.21819. Cancer. 2006. PMID: 16568472 Free article.

3

Prognostic stratification of patients with anaplastic gliomas according to genetic profile.

Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, Benouaich-Amiel A, Pedretti M, Polivka M, Xuan KH, Thillet J, Delattre JY, Sanson M. Dehais C, et al. Cancer. 2006 Oct 15;107(8):1891-7. doi: 10.1002/cncr.22211. Cancer. 2006. PMID: 16986124 Free article.

4

Molecular changes in brain tumors: prognostic and therapeutic impact.

Sanson M, Laigle-Donadey F, Benouaich-Amiel A. Sanson M, et al. Curr Opin Oncol. 2006 Nov;18(6):623-30. doi: 10.1097/01.cco.0000245322.11787.72. Curr Opin Oncol. 2006. PMID: 16988585 Review.

5

The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma.

Vauleon E, Auger N, Benouaich-Amiel A, Laigle-Donadey F, Kaloshi G, Lejeune J, Delattre JY, Thillet J, Sanson M. Vauleon E, et al. Cancer Genet Cytogenet. 2007 Jan 1;172(1):33-7. doi: 10.1016/j.cancergencyto.2006.07.013. Cancer Genet Cytogenet. 2007. PMID: 17175377

6

MGMT methylation: a marker of response to temozolomide in low-grade gliomas.

Everhard S, Kaloshi G, Crinière E, Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY, Thillet J. Everhard S, et al. Ann Neurol. 2006 Dec;60(6):740-3. doi: 10.1002/ana.21044. Ann Neurol. 2006. PMID: 17192931 Clinical Trial.

7

Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.

Ducray F, Benouaich-Amiel A, Idbaih A, Rousseau A, Laigle-Donadey F, Delattre JY, Sanson M. Ducray F, et al. J Neurooncol. 2008 Jun;88(2):185-8. doi: 10.1007/s11060-008-9546-0. J Neurooncol. 2008. PMID: 18317694

8

[Molecular biology of oligodendroglial tumors].

Laigle-Donadey F, Benouaich-Amiel A, Hoang-Xuan K, Sanson M. Laigle-Donadey F, et al. Neurochirurgie. 2005 Sep;51(3-4 Pt 2):260-8. doi: 10.1016/s0028-3770(05)83487-3. Neurochirurgie. 2005. PMID: 16292170 Review. French.

9

Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma.

Carpentier C, Laigle-Donadey F, Marie Y, Auger N, Benouaich-Amiel A, Lejeune J, Kaloshi G, Delattre JY, Thillet J, Sanson M. Carpentier C, et al. Neurology. 2006 Sep 12;67(5):872-4. doi: 10.1212/01.wnl.0000229927.12007.37. Epub 2006 Aug 2. Neurology. 2006. PMID: 16885506

10

Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas.

Kujas M, Lejeune J, Benouaich-Amiel A, Crinière E, Laigle-Donadey F, Marie Y, Mokhtari K, Polivka M, Bernier M, Chretien F, Couvelard A, Capelle L, Duffau H, Cornu P, Broët P, Thillet J, Carpentier AF, Sanson M, Hoang-Xuan K, Delattre JY. Kujas M, et al. Ann Neurol. 2005 Aug;58(2):322-6. doi: 10.1002/ana.20543. Ann Neurol. 2005. PMID: 16049942

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters